Cyr, D D
Allen, A S
Du, G-J
Ruffin, F
Adams, C
Thaden, J T
Maskarinec, S A
Souli, M
Guo, S
Dykxhoorn, D M
Scott, W K
Fowler Jr, V G
Article History
Received: 2 December 2016
Revised: 14 February 2017
Accepted: 16 February 2017
First Online: 23 March 2017
Competing interests
: VGF served as Chair of V710 Scientific Advisory Committee (Merck) and has received grant support from Cerexa/Actavis, Pfizer, Advanced Liquid Logics, NIH, MedImmune, Cubist/Merck, Karius, Contrafect and Genentech. He has NIH STTR/SBIR grants pending from Affinergy and Locus, Medical Surface, Inc.; has been a paid consultant for Achaogen, Astellas, Arsanis, Affinergy, Basilea, Bayer, Cerexa, Contrafect, Cubist, Debiopharm, Durata, Grifols, Genentech, MedImmune, Merck, Medicines Co., Pfizer, Novartis, Novadigm, Theravance and xBiotech; has received honoraria from Theravance and Green Cross; and has a patent pending in sepsis diagnostics. No other authors have any commercial or other association that might pose a conflict of interest.